The Inhibition of Platelet Antiaggregating Activity of Clopidogrel by Atorvastatin Detected by Erythromycin Breath Test: a Metabolic Inhibition of Hepatic Cytochrome P450-3A


Phase N/A Results N/A

Eligibility Criteria

Inclusion Criteria

- Males and females age 18-75 years of age without bias in racial and ethnic background, undergoing percutaneous coronary intervention requiring antiplatelet therapy: 1. Patients presented to cardiology clinic requiring cholesterol lowering agent 2. Patients presented to cardiology clinic requiring antiplatelet agent.

Exclusion Criteria

- Refusal or inability to give written consent
- Allergic reaction to erythromycin
- Have known bleeding problems, liver disease, significant lung disease kidney disease
- Pregnancy
- Psychiatric impairment and documented history of substance abuse